Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (Queensland Investment Corporation), an investment fund with over AU$60 billion under management. He previously was the senior biotechnology analyst at Foster Stockbroking, and advised numerous life sciences companies in corporate finance at Deloitte. Mr Gozlan is a board member of several public and private healthcare companies, and has presented at numerous international life science conferences. He holds a Bachelor of Science with Honours in microbiology and immunology from the University of Melbourne specialising in neurodegenerative diseases.
AusBiotech Chairman, Dr Deborah Rathjen, welcomed Mr Gozlan’s appointment and said his experience and background will be a great addition to the biotechnology industry’s peak body. “It is a pleasure to welcome Lawrence to the AusBiotech Board. His deep experience in global biotech investing will be helpful in bringing forward new initiatives targeting investment into Australian companies.”
Mr Gozlan was pleased to accept the appointment and said: “I am delighted to join the board of AusBiotech during this exciting time in the Australian life sciences industry. By assuming this role, I look forward to helping advance policies that will enable people around the world to benefit from the work that Australian companies carry out.”
The new AusBiotech Board of Directors is:
Dr Deborah Rathjen (Chair)
Dr Anna Lavelle (Chief Executive Officer)
Dr Meera Verma
Ms Michelle Burke
Mr Peter Turvey
Dr Greg Roger
Mr Lawrence Gozlan
Media enquiries:
Lorraine Chiroiu
AusBiotech’s Communications Manager
lchiroiu@ausbiotech.org
P: +61 (0) 3 9828 1414
M: +61 (0) 429 801 118
